Using Polidocanol in Treatment of Simple Renal Cyst

The aim of this study was to assess the efficacy of polidocanol in patients with simple renal cysts who were not eligible for surgery due to comorbidities. Twenty-nine patients with Bosniak type 1 or 2 were assessed retrospectively. All of the cysts were exophytic. All of the patients were injected a maximum 20 mL 3% polidocanol as a sclerosing agent following cyst aspiration. Vanishing of symptoms and decrease in size to 10% of the initial size were accepted as complete remission, decrease in size to 10–50% of the initial size was accepted as partial remission, and a return to the initial size of the cyst in a short time or decrease in size > 50% of the initial size was accepted as failure. The results of an average of 14 months’ follow-up are reported. Complete remission was seen in 18 (62%) patients, partial remission was seen in 5 (17.2%) patients, and failure was observed in 6 (20.68%) patients during an average of 14 months’ follow-up. Percutaneous sclerotherapy using polidocanol can be used safely and with low complication rates in the elderly population with comorbidities.